The global cognitive and memory enhancer drugs market was valued at $3,680 million in 2016, and is projected to reach $6,598 million by 2023, growing at a CAGR of 8.6% from 2017 to 2023. The growth of the global cognitive and memory enhancer drugs market is driven by surge in geriatric population and rise in prevalence of neurological & memory-related disorders. Furthermore, the benefits offered by cognitive drugs such as improved memory and reasoning fuel the market growth. However, ethical issues related to the use of these drugs impede the market growth.
The global cognitive and memory enhancer drugs market is segmented on the basis of product, application, and region. Based on product, the market is categorized into Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall, and others. The applications covered in the study include disease treatment, academic performance, athletic performance, and others. Disease treatment segment is further bifurcated into developmental conditions and neurodegenerative disease. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging trends and dynamics in the global cognitive and memory enhancer drugs market.
This study provides the competitive landscape of the global market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region-and country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Product
Aricept
Exelon
Namenda
Razadyne
Provigil
Ritalin
Adderall
Others
By Application
Disease Treatment
Developmental Conditions
Neurodegenerative Conditions
Academic Performance
Athletic Performance
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
The key players profiled in this report are as follows:
Pfizer Inc.
Eisai Co., Ltd.
Allergan, Inc.
Novartis AG
Shire
Johnson & Johnson
Takeda Pharmaceutical Company Limited
AlternaScript LLC
Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.)
Ceretropic
What is the estimated value of the Global Cognitive and Memory Enhancer Drugs Market?
What is the growth rate of the Global Cognitive and Memory Enhancer Drugs Market?
What is the forecasted size of the Global Cognitive and Memory Enhancer Drugs Market?
Cognitive and memory enhancers are the drugs or supplements, which help to improve the cognitive functions such as memory, creativity, and others in patients suffering from diseases such as neurological disorders as well as in healthy individuals. The major factors that contribute to the market growth include growth in geriatric population prone to neurological disorders such as Alzheimer. Moreover, rise in adoption of cognitive drugs owing to its benefits such as improved physical and mental performance boosts the market growth. However, the ethical issues related with the use of such drugs restrain the growth of this market.
Namenda generated the maximum revenue in the global cognitive and memory enhancer drugs market in 2016, and is expected to dominate the market till 2023. Exelon segment is expected to register the highest CAGR of 10.9% during the forecast period, owing to increase in awareness among people towards improved physical performance.
Disease treatment application segment is expected to dominate the market in the future, owing to increase in the number of patients suffering from neurological diseases such as Alzheimer's. On the other hand, academic performance segment is estimated to exhibit a CAGR of 10.2% during the forecast period
Key findings of the Cognitive And Memory Enhancer Drugs Market:
Razadyne contributed for more than one-sixth share of the global cognitive and memory enhancer drugs market in 2016.
Provigil is projected to grow at a significant CAGR of 10.4% during the analysis period.
Athletic performance is expected to grow at a significant CAGR of 9.8% from 2017 to 2023.
Germany and France were the major shareholders in 2016, together accounting for more than one-third share of the European cognitive and memory enhancer drugs market.
Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific market.
The Asia-Pacific market is projected to grow at the highest CAGR of 9.6% during the forecast period, owing to improvement in healthcare infrastructure and rise in expenditures in the emerging markets (such as India and China) to cater to the unmet medical needs.
The major companies profiled in the report are Pfizer Inc., Eisai Co., Ltd., Allergan, Inc., Novartis AG, Shire, Johnson & Johnson, Takeda Pharmaceutical Company Limited, AlternaScript LLC, Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.), and Ceretropic.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...